Related Experiment Video
Updated: Jun 3, 2026
09:27
Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
Caspofungin therapy in immunocompromised children and neonates
Ayper Somer1, Selda H Törün, Nuran Salman
1Istanbul University, Istanbul Medical Faculty, Department of Pediatric Infectious Diseases, Millet Cad. 34390 Capa, Istanbul, Turkey. ayper.somer@gmail.com
Expert Review of Anti-Infective Therapy
|March 23, 2011
Summary
Caspofungin, a new antifungal, is effective for invasive fungal infections in immunocompromised children and neonates. This review covers its use in treating candidiasis, aspergillosis, and febrile neutropenia.
Area of Science:
- Medical Science
- Pharmacology
- Pediatrics
Background:
- Invasive fungal infections pose a significant threat to immunocompromised children and neonates.
- The development of novel antifungal agents is crucial for managing these infections.
Purpose of the Study:
- To review published data on the efficacy and safety of caspofungin in pediatric populations.
- To assess caspofungin's role in treating invasive candidiasis, aspergillosis, and febrile neutropenia in immunocompromised children and neonates.
Main Methods:
- Literature review of published studies on caspofungin use in pediatric patients.
- Analysis of data concerning treatment of invasive fungal infections in immunocompromised children and neonates.
Main Results:
- Caspofungin, an echinocandin, is approved for invasive candidiasis, salvage therapy for invasive aspergillosis, and empirical therapy for febrile neutropenia in children aged 3 months and older.
- The review synthesizes current evidence on caspofungin's application in this vulnerable patient group.
Conclusions:
- Caspofungin represents a significant advancement in antifungal therapy for pediatric patients.
- Further research and data collection are valuable for optimizing caspofungin use in neonates and immunocompromised children.
Related Concept Videos
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...